Quantum Financial Advisors LLC Has $229,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Quantum Financial Advisors LLC cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 27.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 3,753 shares of the biopharmaceutical company’s stock after selling 1,430 shares during the quarter. Quantum Financial Advisors LLC’s holdings in Bristol-Myers Squibb were worth $229,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Mirador Capital Partners LP lifted its position in shares of Bristol-Myers Squibb by 1.7% in the 1st quarter. Mirador Capital Partners LP now owns 48,166 shares of the biopharmaceutical company’s stock worth $2,938,000 after purchasing an additional 812 shares during the period. Winthrop Advisory Group LLC acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $210,000. Parallel Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 1.4% in the 1st quarter. Parallel Advisors LLC now owns 35,322 shares of the biopharmaceutical company’s stock valued at $2,154,000 after acquiring an additional 471 shares in the last quarter. Tompkins Financial Corp increased its stake in shares of Bristol-Myers Squibb by 2.5% in the 1st quarter. Tompkins Financial Corp now owns 9,151 shares of the biopharmaceutical company’s stock valued at $558,000 after acquiring an additional 225 shares in the last quarter. Finally, Partnership Wealth Management LLC increased its stake in shares of Bristol-Myers Squibb by 1.3% in the 1st quarter. Partnership Wealth Management LLC now owns 28,225 shares of the biopharmaceutical company’s stock valued at $1,721,000 after acquiring an additional 358 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY opened at $48.26 on Friday. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The business has a fifty day moving average price of $50.49 and a 200-day moving average price of $55.37. The company has a market capitalization of $98.21 billion, a PE ratio of -10.92, a PEG ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same period last year, the company earned ($4.40) EPS. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. As a group, equities analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were paid a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.14%. Bristol-Myers Squibb’s dividend payout ratio is currently 92.88%.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the business’s stock in a transaction that occurred on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. UBS Group lowered their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.